摘要
特立帕肽(Teriparatide,TPTD)是甲状旁腺激素(parathyroid hormone,PTH)的1~34位的人工合成多肽,具有促进骨合成代谢、免疫调节等作用,临床已成为治疗骨质疏松的常规药物,并逐渐开发用于颌骨相关疾病。其中,大量证据表明TPTD具有治疗药物相关性颌骨坏死(medication-related osteonecrosis of the jaw,MRONJ)的效应。本综述介绍TPTD治疗MRONJ的最新进展,研究其在治疗MRONJ的潜在价值。
Teriparatide(TPTD),a synthetic peptide corresponding to the first 34 amino acids of human parathyroid hormone(PTH),has been approved for the treatment of osteoporosis for its anabolic and immunoregulatory effects.Such effects inspired clinicians to dig its potential to rescue jaw bone related disease.Among these,an increasing number of research has shown the therapeutic effect of TPTD on medication-related osteonecrosis of the Jaw(MRONJ).However,the exact pathogenesis of TPTD for treating MRONJ remains largely unknown.This review focuses on the progress of TPTD in the management of MRONJ,investigating its potential value on clinical use.
作者
王甲甲
王绍义
WANG Jiajia;WANG Shaoyi(Department of Oral Surgery,Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,College of Stomatology,Shanghai Jiao Tong University,National Center for Stomatology,National Clinical Research Center for Oral Diseases,Shanghai Key Laboratory of Stomatology,Shanghai 200011,China)
出处
《口腔医学研究》
CAS
CSCD
北大核心
2022年第8期718-721,共4页
Journal of Oral Science Research
关键词
特立帕肽
药物性颌骨坏死
治疗
Teriparatide
medication-related osteonecrosis of the jaw
treatment
